JP2015534562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534562A5 JP2015534562A5 JP2015535058A JP2015535058A JP2015534562A5 JP 2015534562 A5 JP2015534562 A5 JP 2015534562A5 JP 2015535058 A JP2015535058 A JP 2015535058A JP 2015535058 A JP2015535058 A JP 2015535058A JP 2015534562 A5 JP2015534562 A5 JP 2015534562A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711136P | 2012-10-08 | 2012-10-08 | |
| US61/711,136 | 2012-10-08 | ||
| PCT/EP2013/070917 WO2014056894A1 (en) | 2012-10-08 | 2013-10-08 | Mek inhibitors in the treatment of virus diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018025712A Division JP2018118971A (ja) | 2012-10-08 | 2018-02-16 | ウイルス疾患の処置におけるｍｅｋ阻害物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534562A JP2015534562A (ja) | 2015-12-03 |
| JP2015534562A5 true JP2015534562A5 (OSRAM) | 2016-11-24 |
| JP6294889B2 JP6294889B2 (ja) | 2018-03-14 |
Family
ID=49552318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535058A Expired - Fee Related JP6294889B2 (ja) | 2012-10-08 | 2013-10-08 | ウイルス疾患の処置におけるｍｅｋ阻害物質 |
| JP2018025712A Pending JP2018118971A (ja) | 2012-10-08 | 2018-02-16 | ウイルス疾患の処置におけるｍｅｋ阻害物質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018025712A Pending JP2018118971A (ja) | 2012-10-08 | 2018-02-16 | ウイルス疾患の処置におけるｍｅｋ阻害物質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9566281B2 (OSRAM) |
| EP (1) | EP2903649A1 (OSRAM) |
| JP (2) | JP6294889B2 (OSRAM) |
| KR (1) | KR102174576B1 (OSRAM) |
| CN (2) | CN105101999B (OSRAM) |
| AU (1) | AU2013328824B2 (OSRAM) |
| BR (1) | BR112015007616B1 (OSRAM) |
| CA (1) | CA2886138C (OSRAM) |
| EA (1) | EA028605B1 (OSRAM) |
| WO (1) | WO2014056894A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| KR102174576B1 (ko) * | 2012-10-08 | 2020-11-06 | 아트리바 테라퓨틱스 게엠베하 | 바이러스 질환 치료에서의 ｍｅｋ 억제제 |
| BR112016026556A8 (pt) | 2014-05-16 | 2021-07-06 | Atriva Therapeutics Gmbh | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção |
| US20190183855A1 (en) * | 2016-08-10 | 2019-06-20 | Riken | Composition for treating hepatitis b, and method for evaluating replication activity of hepatitis b virus |
| WO2018095403A1 (zh) * | 2016-11-25 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | 一种吡啶酮类衍生物药物组合物及其制备方法 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| JP7227967B2 (ja) * | 2017-10-17 | 2023-02-22 | アトリバ セラピューティクス ゲーエムベーハー | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| US20190298669A1 (en) * | 2018-03-29 | 2019-10-03 | Atriva Therapeutics Gmbh | Ci-1040 for the treatment of viral diseases |
| DK3860598T3 (da) | 2018-10-03 | 2023-10-16 | Jyvaeskylaen Yliopisto | Vemurafenib og salte heraf til anvendelse til behandling af enterovirusinfektioner |
| CN109765324B (zh) * | 2018-11-27 | 2021-03-30 | 苏州科技大学 | 一种mek1蛋白潜在抑制剂的筛选方法 |
| CA3133044A1 (en) | 2019-03-19 | 2020-09-24 | Atriva Therapeutics Gmbh | Rsk inhibitors in the treatment of virus diseases |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| BR112022003673A2 (pt) | 2019-08-27 | 2022-05-24 | Atriva Therapeutics Gmbh | Combinações de inibidores de mek com inibidores de endonuclease dependente de cap |
| KR20220079573A (ko) | 2019-10-08 | 2022-06-13 | 아트리바 테라퓨틱스 게엠베하 | 한타바이러스 감염의 치료를 위한 mek 억제제 |
| WO2021214296A1 (en) * | 2020-04-24 | 2021-10-28 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Treatment of corona virus infections |
| CN111494620A (zh) * | 2020-05-05 | 2020-08-07 | 华中科技大学同济医学院附属协和医院 | 曲美替尼在制备疫苗中的应用 |
| CN111529532A (zh) * | 2020-05-05 | 2020-08-14 | 华中科技大学同济医学院附属协和医院 | 曲美替尼在制备治疗肺部炎症性疾病药物及促进Tfh细胞分化药物中的应用 |
| CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0553107B1 (en) | 1990-07-30 | 1999-09-29 | Procyon Pharmaceuticals, Inc. | Protein kinase c modulators with anti-inflammatory and antiviral activity |
| US5866601A (en) | 1995-02-27 | 1999-02-02 | Gilead Sciences, Inc. | Carbocyclic compounds |
| US5763483A (en) | 1995-12-29 | 1998-06-09 | Gilead Sciences, Inc. | Carbocyclic compounds |
| CA2358438A1 (en) * | 1999-01-07 | 2000-07-13 | David Thomas Dudley | Antiviral method using mek inhibitors |
| DE10017480A1 (de) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| DE10138912A1 (de) | 2001-08-08 | 2003-02-27 | Medinnova Ges Med Innovationen | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen |
| PL1893612T3 (pl) * | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| CN102036658A (zh) * | 2008-05-23 | 2011-04-27 | 香港大学 | 治疗流感的联合疗法 |
| KR102174576B1 (ko) * | 2012-10-08 | 2020-11-06 | 아트리바 테라퓨틱스 게엠베하 | 바이러스 질환 치료에서의 ｍｅｋ 억제제 |
-
2013
- 2013-10-08 KR KR1020157010311A patent/KR102174576B1/ko active Active
- 2013-10-08 EA EA201590703A patent/EA028605B1/ru active IP Right Revival
- 2013-10-08 BR BR112015007616-5A patent/BR112015007616B1/pt active IP Right Grant
- 2013-10-08 CN CN201380064116.5A patent/CN105101999B/zh active Active
- 2013-10-08 AU AU2013328824A patent/AU2013328824B2/en not_active Ceased
- 2013-10-08 CA CA2886138A patent/CA2886138C/en active Active
- 2013-10-08 CN CN201810617076.7A patent/CN109276716B/zh active Active
- 2013-10-08 US US14/434,328 patent/US9566281B2/en not_active Expired - Fee Related
- 2013-10-08 WO PCT/EP2013/070917 patent/WO2014056894A1/en not_active Ceased
- 2013-10-08 JP JP2015535058A patent/JP6294889B2/ja not_active Expired - Fee Related
- 2013-10-08 EP EP13788684.2A patent/EP2903649A1/en not_active Withdrawn
-
2017
- 2017-02-09 US US15/428,693 patent/US20170209450A1/en not_active Abandoned
-
2018
- 2018-02-16 JP JP2018025712A patent/JP2018118971A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534562A5 (OSRAM) | ||
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| MX2024010140A (es) | Nuevos metodos. | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| UA117095C2 (uk) | Нуклеозидна сполука або її фармацевтично прийнятна сіль | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| JP2016518337A5 (OSRAM) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX388946B (es) | Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos. | |
| MX383706B (es) | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| MX376012B (es) | Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas. | |
| BR112014010105A2 (pt) | aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| GEP201606531B (en) | Inhibitors of influenza viruses replication | |
| MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| MX387125B (es) | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. | |
| BR112012017691A2 (pt) | nova composição | |
| JP2017515840A5 (OSRAM) | ||
| HRP20241552T1 (hr) | Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost | |
| JP2015516419A5 (OSRAM) | ||
| JP2016540000A5 (OSRAM) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. |